Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company developing targeted radiopharmaceutical therapies for the treatment of cancer. The company develops targeted alpha therapies (TATs), which are radiopharmaceuticals designed for cancer treatment, utilizing proprietary Fast-Clear linker technology to connect alpha-emitting isotopes to targeting molecules such as antibodies and small molecules. Its product pipeline includes candidates such as FPI-2265 for prostate cancer, FPI-1434 for solid tumors, and FPI-2059 for tumors expressing neurotensin receptor 1, along with imaging analogues like FPI-1547 for patient screening and dosimetry. The company conducts clinical trials to evaluate the safety, tolerability, and efficacy of these therapies, including combination studies with other oncology treatments. It also offers partnering opportunities related to its linker technology and targeted alpha therapy platform. The company was founded in 2014 and is based in Hamilton, Canada.